semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 21.0-30.0,  Alcohol Drinking Alcohol Use Disorder Alcohol Intoxication Alcohol; Harmful Use Alcoholism Binge Drinking Between the ages of 21 and 30 Currently drinks alcohol Able to provide at least 2 same-gender friend referrals  Female participant is pregnant or trying to become pregnant Endorsed medical disorder caused by, or made worse by, alcohol History of severe alcohol problems Use of drugs known to interact with alcohol
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Cancer, Metastatic Cancer Cancer of Pancreas Cancer of Liver Cancer of Stomach Cancer Liver Cancer of Rectum Cancer of Kidney Cancer of Esophagus Cancer of Cervix Cancer of Colon Cancer of Larynx Cancer, Lung Cancer, Breast Cancer, Advanced Cancer Prostate Cancer of Neck Cancer of Skin Neuroendocrine Tumors Carcinoma Mismatch Repair Deficiency BRCA Gene Rearrangement Non Hodgkin Lymphoma Leukemia Non Small Cell Lung Cancer Cholangiocarcinoma Glioblastoma Central Nervous System Tumor Melanoma Urothelial Carcinoma Bladder Cancer Ovarian Cancer Endometrial Cancer Testicular Cancer Breast Cancer COVID Pts with solid and hematological malignancies Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2, Tumor mutational burden/load (TMB), ABL1, ACVR1B, AKT1, AKT2, AKT3, ALK, APC, AR, ATM, ATRX, AURKA, AURKB, BAP1, BCL2, BCL6, BRAF, BRCA1, BRCA2, BTK, CCND1, CCND2, CCND3, CDK4, CDK6, CDKN1A/B, CEBPA, CHEK1, CHEK2, CSF1R, CTNNB1, DAXX, DDR1/2, DNMT3A, EGFR, ERBB2, ERBB3, ERBB4, ERCC4, ER, ESR1, FANCA, FAS, FBXW7, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GATA3, GATA6, GNAS, HDAC1, HGF, HRAS, IDH1, IDH2, IGF1R, JAK1, JAK2, JAK3, KDR (VEGFR2), KIT, KRAS, MAP2K2 (MEK2), MAP3K1, MCL1, MDM2, MDM4, MEN1, MET, MSH2, MSH3, MSH6, MTOR, MUTYH, MYC, MYCL (MYCL1), NF1, NF2, NOTCH1, NPM1, NRAS, NTRK1, NTRK2, NTRK3, PALB2, PARP1, PARP2, PARP3, PBRM1, PDCD1 (PD1), PDCD1LG2 (PD-L2), PIK3C, PMS2, POLD1, POLE, PRDM1, PTCH1, PTEN, RAF1, RB1, RET, ROS1, RPTOR, SDHA/B/C, SMAD, SMARC, SMO, STK11, TGFBR2, TP53, TSC1, TSC2, VEGFA, VHL, WT1, ZNF217, ZNF703, among others. These biomarkers should be determined by local laboratory, external vendor, or next generation sequencing platform Decision to consider clinical trial pre-screening enrollment (CTE) by primary provider and/or patient  ECOG PS > 2 Abnormal organ function Hospice enrollment
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cervical Cancer Screening One previous routine screening Pap test showing ASC-US, HPV positive Two previous consecutive routine screening Pap tests showing ASC-US or LSIL  previous hysterectomy pregnant or considering pregnancy in the next 18 months had a previous excisional or ablative procedure of the cervix younger than 18
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 21.0-29.0,  Alcohol Drinking Alcohol Use Disorder Alcohol Intoxication Alcohol; Harmful Use Alcoholism Binge Drinking to 29 years of age currently drinks alcohol owns a smartphone  are masked from public viewing until data collection is complete. Please contact project managers.]
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Cervical Cancer Stage IIIB Treatment Outcome Follow up QUESTIONNAIRE Cervical Cancer Stage Ib2, II and III (Squamous carcinoma or adenocarcinoma) 2. Cancer of the vault 3. Cancer of the cervix which inadvertently underwent hysterectomy (inadequate surgery) 4. Treated with curative intent with radical radio(chemo)therapy or NACT followed by radical radio(chemo)therapy and completed all curative treatment. 5. Within 2 years post completion of treatment 6. Has complete clinical response at 3 months post treatment 7. Informed consent 8. Contactable by telephone  Patients with Stage III disease treated with palliative intent with once monthly radiotherapy 2. Early stage cervical cancer patients who underwent Wertheims hysterectomy and who have completed adjuvant radiochemotherapy due to high-risk factors 3. Metastatic cervical cancers 4. Patients who are unable to comprehend the questions or dialogue over telephone by medical staff. 5. Patients who seem unreliable for follow up
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Obstetric Complication Postpartum Hemorrhage Postpartum Endometritis Female Able to give consent Gestational age > 24 weeks Postpartum Placement of an IBT within the last 2 hours with plans for it to remain in situ for at least 2 hours Primary obstetrician amenable to proceeding with either method of management during the study period  Age < 18 years old IBT removed within 2 hours of placement Chorioamnionitis Insufficient documentation of demographics, delivery outcomes, or peripartum events including postpartum hemorrhage, infectious outcomes
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 30.0-999.0,  Patient Adherence In the Randomized Controlled Trial we will recruit a minimum of 4000 women, aged 30 and older living in the province of Jujuy, Argentina. are: 1. Having performed self-collection of HPV-testing. 2. Mentally competent to understand the consent form. 3. Able to communicate with study staff. 4. Being able to provide a mobile phone telephone number  Current pregnancy Women with Mental disability
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 9.0-26.0,  Prevention of HPV Types 16- and 18-related Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN) 1/2/3, and Cervical Adenocarcinoma in Situ Not pregnant and 1) not a woman of childbearing potential (WOCBP), or 2) a WOCBP who has not had sex with males or has had sex with males and used effective contraception since the first day of participant's last menstrual period through Day 1 and understands and agrees that during the study she should not have sexual intercourse with males without effective contraception (the rhythm method, withdrawal, and emergency contraception are not acceptable methods per the protocol) Participant and participant's parent or guardian (participants aged 9-17 years only) provided written informed consent/assent Provided a primary and alternative telephone for follow-up purposes Extension Stage: participant was enrolled in the 9-19 years old group, received 3 doses of V501 in the Base Stage, and participant and participant's legally acceptable representative (if applicable) provided written informed consent/assent for the study extension  History of severe allergic reaction that required medical intervention Allergic to any vaccine component, including aluminum, yeast, or Benzonase® (nuclease) Known thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections Currently immunocompromised or was diagnosed as having congenital or acquired immunodeficiency, human immunodeficiency virus (HIV) infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), inflammatory bowel disease, or other autoimmune condition History of splenectomy Any condition which in the opinion of the investigator might interfere with the evaluation of the study objectives History of recent or ongoing alcohol or other drug abuse History of a positive test for HPV Any history of abnormal Pap test History of external genital wart, vulvar intraepithelial neoplasia (VIN), vaginal intraepithelial neoplasia (VaIN), vulvar cancer or vaginal cancer
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Cervical Cancer For FP Clinics All FP clinics that receive County-supplied FP products will be eligible to participate  Any clinic that is expected to be closed during part or all of the SAIA intervention period will be excluded. Any FP clinic that was previously included in the FP HIV SAIA trial will be excluded. FP clinic managers and staff Any FP clinic manager that is 18 years and older is eligible to be interviewed These clinic managers can be male or female
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 21.0-40.0,  Alcohol Drinking Weight Loss Adiposity Obesity Visceral Obesity Pre-menopausal women only 40 years of age BMI 27-50 kg/m2 (+/ 5 will be accepted) Must practice and be willing to continue to practice appropriate birth control (defined as a method which results in a low failure rate, i.e., less than 1% per year, when used consistently and correctly, such as double barrier methods [male condom with spermicide, with or without cervical cap or diaphragm], implants, intrauterine contraceptive devices, tubal ligation (surgically sterile), abstinence, or in an established relationship with a vasectomized or same sex partner) during the entire duration of the study Must be willing to adhere to all study procedures, including consumption of all study foods and beverages and attendance at all study visits Must be willing to eat at least one meal at PBRC 3 times per week on weekdays (excluding holidays) Must be willing to consume alcohol Must be willing to abstain from alcohol for 8-weeks if randomized to non-alcohol control group Must be a daily, or almost daily drinker, defined as typically consuming at least 8 drinks per week, but no more than 4 per day  Non-drinkers of alcohol Habitual binge drinkers, as defined by the consumption of ≥ 4 standard drinks per day or ≥ 28 drinks per week Self-reported alcoholics or a history of alcoholism Have a 1st degree relative with alcoholism Any attendance or inpatient stay for alcohol or drug treatment Display any characteristics of current or future substance abuse disorders Presence of any psychiatric, behavioral, or medical disorder that, in the opinion of the PIs, Co-I, or MI, may interfere with study participation, the ability to adhere to the protocol, or has the potential for increased substance abuse Prescription medications that interact with alcohol intake Abnormal screening laboratory safety tests Smokers
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 9.0-26.0,  Papillomavirus Infections Uterine Cervical Neoplasms Vulvar Neoplasms Vaginal Neoplasms Adenocarcinoma in Situ Condylomata Acuminata In good physical health Participants 9 to 15 years of age: has not had coitarche and do not plan on becoming sexually active during the study Participants 16 to 26 year of age: has never had Papanicolaou (Pap) testing or has had only normal Pap test results. Has a lifetime history of ≤4 male and/or female sexual partners Female participants 16 to 26 years of age: has not had sex with males or has had sex with males and used effective contraception, and understands and agrees that during the study she should not have sexual intercourse with males without effective contraception (rhythm method, withdrawal, and emergency contraception are not acceptable methods of contraception per-protocol)  Known allergy to any vaccine component, including aluminum, yeast, or History of severe allergic reaction that required medical intervention Has thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections Concurrently enrolled in clinical studies of investigational agents Immunocompromised or has been diagnosed with congenital or acquired immunodeficiency, human immunodeficiency virus (HIV) infection, lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other autoimmune condition Had a splenectomy User of recreational or illicit drugs or has had a recent history (within the last year) of drug abuse or dependence. Alcohol abusers are defined as those who drink despite recurrent social, interpersonal, and/or legal problems as a result of alcohol use History of a positive test for HPV Male participants 16 to 26 years of age: history of HPV-related external genital lesions (e.g., condyloma acuminata) or HPV-related anal lesions (e.g., condyloma acuminata, or anal intraepithelial neoplasia) or anal cancer Female participants 16 to 26 years of age: history of an abnormal cervical biopsy result (showing cervical intraepithelial neoplasia or worse)
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-120.0,  Glottic Carcinoma Pathologically-proven diagnosis of squamous cell carcinoma in situ, squamous cell carcinoma or squamous cell variants (sarcomatoid, verrucous, basaloid, and papillary subtypes) involving the glottic larynx. 2. Clinical stage I-II (American Joint Committee on Cancer AJCC, 7th edition) with direct laryngoscopy showing no evidence of greater than stage II true glottic larynx cancer and PET/CT or CT neck showing no evidence of regional disease. 3. Age ≥ 18 years. 4. ECOG Performance Status 0-2 5. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. 5.1 A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following Has not undergone a hysterectomy or bilateral oophorectomy; or Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months). 6. Negative serum or urine pregnancy test within 2 weeks before registration for women of childbearing potential. 7. Ability to understand and the willingness to sign a written informed consent. 8. Patients with cognitive impairment or other limited decision making capacity with the ability to understand and willingly sign written informed consent or have the consent signed by a designated legally authorized representative (LAR)  AJCC stage III or stage IV larynx cancer 2. Involvement of the arytenoid cartilage beyond the vocal process. 3. Prior chemotherapy for treatment of the targeted larynx lesion 4. Synchronous primaries in the head and neck 5. Prior radiotherapy to the region of the study cancer that would result in overlap of radiation fields. 6. Subjects smoking in excess of 1 pack of cigarettes per day. 7. Subjects may not be receiving any other investigational agents. 8. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. 9. Subjects must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Neoplasms Ability to understand and the willingness to sign a written informed consent. 2. 18-75 year old patients with newly-diagnosed cancer scheduled to undergo anthracycline-based chemotherapy (minimum of 200 mg/m2 of doxorubicin or equivalent) at UCSD Medical Center. 3. Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. • A woman of child-bearing potential is any female (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following Has not undergone a hysterectomy or bilateral oophorectomy; or Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months) 4. Women of child-bearing potential must have a negative pregnancy test during the screening period  Prior chemotherapy with anthracycline; 2. Persistent tachycardia (heart rate>90); 3. LVEF<53% or history of cardiomyopathy or decompensated heart failure; 4. Baseline GLS below lower limit of normal (normal range varies depending on age and gender (23)) or inability to obtain meaningful strain data due to poor quality of Echocardiographic images; 5. Known unrevascularized coronary artery disease, myocardial infarction within 30 days of enrollment; 6. Moderate or severe valvular heart disease; 7. Prior allergy or intolerance to iodinated contrast; 8. Renal failure (GFR<30, creatinine >1.5); 9. Cancer involvement of the heart
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Surgery--Complications Patients diagnosed with FIGO stage IA2-IB1-IIA1 cervical cancer Subjected to Radical Hysterectomy  Pregnant women in which a RH was performed at the time of caesarean section Previous chemotherapy treatment Previous pelvic radiotherapy
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  High Grade Ovarian Serous Adenocarcinoma Stage III Ovarian Cancer AJCC v8 Stage IIIA Ovarian Cancer AJCC v8 Stage IIIA1 Ovarian Cancer AJCC v8 Stage IIIA2 Ovarian Cancer AJCC v8 Stage IIIB Ovarian Cancer AJCC v8 Stage IIIC Ovarian Cancer AJCC v8 Stage IV Ovarian Cancer AJCC v8 Stage IVA Ovarian Cancer AJCC v8 Stage IVB Ovarian Cancer AJCC v8 With suspected advanced ovarian cancer Planned surgery Have a uterus and no history of tubal occlusion  Unable to speak English Unable to provide informed consent Prior hysterectomy
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 30.0-65.0,  Cervical Cancer Jamaican women, aged 30 to 65  Women who report having had a hysterectomy have had a history of cervical cancer Women who are currently up-to-date on cervical cancer screening (have had a Pap in the last 3 years or have had a Pap smear/HPV co-test within the past 5 years) Adults unable to consent, children, pregnant women and prisoners